Cargando…

Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer

PURPOSE: Immune checkpoint inhibitors (ICIs) have recently emerged as an important option for treating patients with advanced non-small cell lung cancer (NSCLC). Neoantigens are important biomarkers and potential immunotherapy targets that play important roles in the prognosis and treatment of patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Hongge, Xu, Yan, Chen, Minjiang, Zhao, Jing, Zhong, Wei, Liu, Xiaoyan, Gao, Xiaoxing, Li, Shanqing, Li, Ji, Guo, Chao, Jia, He, Wang, Mengzhao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959482/ https://www.ncbi.nlm.nih.gov/pubmed/35356154 http://dx.doi.org/10.3389/fimmu.2021.749461

Ejemplares similares

Prognostic Factors and Survival Benefits of Antitumor Treatments for Advanced Non-Small Cell Lung Cancer Patients With Central Nervous System Metastasis With or Without Driver Genes: A Chinese Single-Center Cohort Study
por: Gao, Xiaoxing, et al.
Publicado: (2022)

Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
por: Miao, Kang, et al.
Publicado: (2022)

Corrigendum: Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non– small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2022)

Mutation-Derived Neoantigens for Cancer Immunotherapy
por: Castle, John C., et al.
Publicado: (2019)

Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib
por: Liang, Hongge, et al.
Publicado: (2019)

Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient
por: Chen, Minjiang, et al.
Publicado: (2021)

Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy
por: Efremova, Mirjana, et al.
Publicado: (2017)

Prognostic impact of maximum standardized uptake value on (18)F‐FDG PET/CT imaging of the primary lung lesion on survival in advanced non‐small cell lung cancer: A retrospective study
por: Qiu, Xiaoling, et al.
Publicado: (2021)

Study protocol of KeyPemls‐004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non‐small cell lung cancer and progressive disease (PD) after immunotherapy (PD‐1/PD‐L1 inhibitor) alone or in combination with platinum‐doublet chemotherapy
por: Liu, Jia, et al.
Publicado: (2023)

Neoantigen: A New Breakthrough in Tumor Immunotherapy
por: Zhang, Zheying, et al.
Publicado: (2021)

Determinants for Neoantigen Identification
por: Garcia-Garijo, Andrea, et al.
Publicado: (2019)

Neoantigens in Hematologic Malignancies
por: Biernacki, Melinda A., et al.
Publicado: (2020)

Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment
por: Liang, Hongge, et al.
Publicado: (2018)

Prognostic role of circulating tumor cells in patients with EGFR‐mutated or ALK‐rearranged non‐small cell lung cancer
por: Tong, Bing, et al.
Publicado: (2018)

Circulating tumor cells PD‐L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non‐small‐cell lung cancer
por: Zhou, Qing, et al.
Publicado: (2023)

Identification of Clonal Neoantigens Derived From Driver Mutations in an EGFR-Mutated Lung Cancer Patient Benefitting From Anti-PD-1
por: Wu, Di, et al.
Publicado: (2020)

Positive tumour CD47 expression is an independent prognostic factor for recurrence in resected non-small cell lung cancer
por: Xu, Yan, et al.
Publicado: (2020)

Identification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients
por: Bräunlein, Eva, et al.
Publicado: (2017)

The Neoantigen Landscape of Mycosis Fungoides
por: Sivanand, Arunima, et al.
Publicado: (2020)

Editorial: The Clinical Application of Neoantigens
por: Zhou, Jian-Guo, et al.
Publicado: (2022)

Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer
por: Chen, Minjiang, et al.
Publicado: (2019)

Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy
por: Guo, Yugang, et al.
Publicado: (2018)

Clinicopathological characteristics of lung cancer in patients with systemic sclerosis
por: Chen, Minjiang, et al.
Publicado: (2020)

Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria
por: Liang, Hongge, et al.
Publicado: (2020)

Feasibility and reliability of evaluate PD‐L1 expression determination using small biopsy specimens in non‐small cell lung cancer
por: Chen, Minjiang, et al.
Publicado: (2021)

TSNAD: an integrated software for cancer somatic mutation and tumour-specific neoantigen detection
por: Zhou, Zhan, et al.
Publicado: (2017)

Structure Based Prediction of Neoantigen Immunogenicity
por: Riley, Timothy P., et al.
Publicado: (2019)

The development of a tumor‐associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor‐based treatment in patients with advanced non‐small‐cell lung cancer
por: Zhao, Jing, et al.
Publicado: (2023)

Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer
por: Liang, Hongge, et al.
Publicado: (2019)

Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
por: Zou, Xue-lin, et al.
Publicado: (2021)

Computational Prediction and Validation of Tumor-Associated Neoantigens
por: Roudko, Vladimir, et al.
Publicado: (2020)

Neoantigens in Hematological Malignancies—Ultimate Targets for Immunotherapy?
por: Roerden, Malte, et al.
Publicado: (2019)

Editorial: Autoimmune Diabetes: Molecular Mechanisms and Neoantigens
por: Kent, Sally C., et al.
Publicado: (2022)

Neoantigens and NK Cells: “Trick or Treat” the Cancers?
por: Lv, Dan, et al.
Publicado: (2022)

Designing neoantigen cancer vaccines, trials, and outcomes
por: Biswas, Nupur, et al.
Publicado: (2023)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
por: Liang, Hongge, et al.
Publicado: (2020)

Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis
por: Gao, Xiaoxing, et al.
Publicado: (2022)

Prognostic significance of circulating tumor cells in non-small cell lung cancer patients undergoing chemotherapy
por: Tong, Bing, et al.
Publicado: (2017)

Computational Pipeline for the PGV-001 Neoantigen Vaccine Trial
por: Rubinsteyn, Alex, et al.
Publicado: (2018)

Improvement of Neoantigen Identification Through Convolution Neural Network
por: Hao, Qing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_elsdumfddn4ci2op2h89gqnjj5